Abstract
Vismodegib, a Smoothened antagonist, is clinically approved for treatment of human basal cell carcinoma (BCC), in the clinical trials of medulloblasto......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
